+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
By Cary Miller, Amy Mills, and Aaron Parker, Morrison & Foerster
The Supreme Court of the United States delivered its much-anticipated and historic ruling in National Federation of Independent Business v. Sebelius June 28, holding the major provisions of the Patient Protection and Affordable Care Act (Affordable Care Act) to be constitutional (10 PLIR 825, 6/29/12). While much of the public debate and commentary focused on the validity of the individual health insurance mandate, the Affordable Care Act also contains important provisions for the development and regulatory approval of biosimilars. Although these provisions were not challenged, questions of severability placed them in jeopardy along with the whole of the Act. The 5-4 Supreme Court decision leaves the Affordable Care Act, including the biosimilars provisions, largely unchanged.
Part of the Affordable Care Act—the Biologics Price Competition and Innovation Act (BPCIA)—created a Food and Drug Administration (FDA) approval pathway for “biosimilars,” follow-on versions of biopharmaceutical products such as therapeutic proteins and antibodies. The BPCIA permits manufacturers of these follow-on versions to rely on previously disclosed pre-clinical and clinical trial data for the safety and efficacy of the biologic products, so long as the sponsor demonstrates that it (i) is “biosimilar” to a reference product (a different standard than the “bioequivalence” requirement for generic drugs), (ii) uses the same mechanism of action as the reference product, and (iii) is being proposed for previously approved condition(s) of use. In some cases, the FDA may deem a biosimilar product “interchangeable” with the reference product, providing other advantages. The BPCIA also provides a complex framework for resolving patent disputes between sponsors of a biosimilar product and the reference biologic product and resolved long-running disputes by specifying exclusivity periods for reference and certain follow-on biologics.
The main focus of the Affordable Care Act, however, was to change the way Americans purchase private health insurance, access public and private providers, and receive coverage for pre-existing conditions, seeking to extend private health care access to 30 million previously uninsured Americans. To this end, the so-called “individual mandate” requires that most Americans maintain minimal essential health insurance coverage or pay a penalty, while the “Medicaid expansion” provision expands the scope of the Medicaid program. Twenty-six states and other parties challenged the constitutionality of these two provisions. The Supreme Court granted certiorari on appeal from an Eleventh Circuit decision, which found the individual mandate unconstitutional.
In a 5-4 decision, the Supreme Court upheld the individual mandate under Congress's power to tax, and placed limits on the Medicaid expansion. Other than limiting the Medicaid expansion, the decision leaves the Affordable Care Act, including the BPCIA, unchanged.
While the decision leaves the BPCIA intact, uncertainty remains regarding the criteria for biosimilar approval, interchangeability standards, and procedures for patent litigation relating to biosimilars. In February, the FDA issued three draft guidance documents on biosimilar product development, focusing on scientific and quality considerations in demonstrating biosimilarity of a proposed product and not addressing product interchangeability or litigation particulars (10 PLIR 173, 2/10/12).
The FDA solicited public comments on the draft guidances, receiving greater than 100 written comments and several presentations made during a May 11 hearing. Among the commenters were major brand and generic drug-makers, universities, members of Congress, foreign governments, and various organizations and advocacy groups. Concerns included the definition of “protein” under the Public Health Services Act, biosimilar naming and labeling requirements, interchangeability standards, trade secret protection, and the ability to rely on data from non-U.S. approved drugs.
The guidance documents remain in draft form and are unaffected by the decision. Some expect the next direction from the FDA to be in the form of class-specific guidances, with details relevant to approval of particular types of biosimilars, such as therapeutic antibodies.
Meanwhile, in April, Abbott Laboratories filed a citizen petition, requesting that biologics applications submitted to the FDA before enactment of the BPCIA be exempt from the BPCIA, asserting that the FDA's use of information in those biologics applications would constitute a taking of trade secrets and a violation of the Fifth Amendment (10 PLIR 597, 5/4/12). (Docket No. FDA-2012-P-0317-0001/CP.) The FDA has not issued a substantive response to Abbott Labs's citizen petition.
While the Court's ruling in National Federation of Independent Business leaves the BPCIA unchanged and available as a potential pathway for the approval of follow-on biologics, industry players await further clarity on navigating its various provisions in light of these continued uncertainties.
Cary Miller (firstname.lastname@example.org) is of counsel in the Patent Group in Morrison & Foerster's San Diego office. Amy Anzelon Mills (email@example.com) is an associate in the Patent Group of the firm's San Diego office. Aaron Parker is a summer associate in the San Diego office of Morrison & Foerster.
© 2012 Morrison & Foerster LLP
This document and any discussions set forth herein are for informational purposes only, and should not be construed as legal advice, which has to be addressed to particular facts and circumstances involved in any given situation. Review or use of the document and any discussions does not create an attorney-client relationship with the author or publisher. To the extent that this document may contain suggested provisions, they will require modification to suit a particular transaction, jurisdiction or situation. Please consult with an attorney with the appropriate level of experience if you have any questions. Any tax information contained in the document or discussions is not intended to be used, and cannot be used, for purposes of avoiding penalties imposed under the United States Internal Revenue Code. Any opinions expressed are those of the author. The Bureau of National Affairs, Inc. and its affiliated entities do not take responsibility for the content in this document or discussions and do not make any representation or warranty as to their completeness or accuracy.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).